Editorial: mitigating primary nonresponse to infliximab-are we better equipped now?

Aliment Pharmacol Ther. 2018 Feb;47(3):434-435. doi: 10.1111/apt.14455.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Antirheumatic Agents*
  • Humans
  • Infliximab*

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Infliximab